Alzinova Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
10
- Stock Symbol
-
ALZ
- Share Price
-
$0.03
- (As of Friday Closing)
Alzinova General Information
Description
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is developing ALZ-101, an oligomer-specific therapeutic vaccine currently advancing toward Phase 2 clinical development, and ALZ-201, a monoclonal antibody targeting toxic amyloid-beta (AB) oligomers, which is in preclinical development. The company's proprietary ABCC peptide technology is focused on disease-modifying treatments for Alzheimer's disease.
Contact Information
Website
www.alzinova.comCorporate Office
- Erik Dahlbergsgatan 11 A
- 411 26 Gothenburg
- Sweden
Corporate Office
- Erik Dahlbergsgatan 11 A
- 411 26 Gothenburg
- Sweden
Alzinova Stock Performance
As of 13-Nov-2026, Alzinova’s stock price is $0.03. Its current market cap is $10M with 316M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.03 | $0.03 | $0.03 - $0.21 | $10M | 316M | 2.46M | -$0.02 |
Alzinova Financials Summary
As of 30-Jun-2026, Alzinova has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 9,173 | 9,362 | 25,516 | 10,231 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (2,404) | (2,606) | (1,927) | (1,554) |
| Net Income | (2,598) | (2,673) | (1,943) | (1,550) |
| Total Assets | 16,834 | 15,587 | 12,075 | 12,326 |
| Total Debt | 0 | 87 | 73 | 80 |
Alzinova Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alzinova Patents
Alzinova Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024238598-A1 | Humanised antibody against amyloid beta 42 | Pending | 20-Mar-2023 | ||
| EP-4683940-A1 | Humanised antibody against amyloid beta 42 | Pending | 20-Mar-2023 | ||
| WO-2024194298-A1 | Humanised antibody against amyloid beta 42 | Inactive | 20-Mar-2023 | ||
| EP-2497782-A1 | Anti oligomer antibodies and uses thereof | Inactive | 08-Mar-2011 | ||
| EP-2683738-A1 | Anti oligomer antibodies and uses thereof | Active | 08-Mar-2011 | C07K16/18 |
Alzinova Signals
Alzinova Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Alzinova ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Alzinova FAQs
-
When was Alzinova founded?
Alzinova was founded in 2011.
-
Where is Alzinova headquartered?
Alzinova is headquartered in Gothenburg, Sweden.
-
What is the size of Alzinova?
Alzinova has 10 total employees.
-
What industry is Alzinova in?
Alzinova’s primary industry is Drug Discovery.
-
Is Alzinova a private or public company?
Alzinova is a Public company.
-
What is Alzinova’s stock symbol?
The ticker symbol for Alzinova is ALZ.
-
What is the current stock price of Alzinova?
As of 13-Nov-2026 the stock price of Alzinova is $0.03.
-
What is the current market cap of Alzinova?
The current market capitalization of Alzinova is $10M.
-
What is Alzinova’s annual earnings per share (EPS)?
Alzinova’s EPS for 12 months was -$0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process